Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2- early breast cancer (EBC): 4-year outcomes from the NATALEE trial [LBA13] - Fasching, P A; Stroyakovskiy, D; Yardeley, D (Ann Oncol, 2025)
et al.